Anakinra Biosimilar Candidate

Anakinra Biosimilar Candidate
Product Description

Paras Biopharmaceuticals has been intensively working on a Anakinra / IL1-RA biosimilar known as Kineret™) and has progressively achieved success. The company plans to mature good value within its Anakrina / IL1-RA asset and would like to highlight the following points / highlights to gauge your level of interest. Kineret™ (originator – Sobi) indicated for the treatment to 1) reduce the signs and symptoms and slow the damage of moderate to severe active rheumatoid arthritis (RA) in people aged 18 years and older, 2) treat people with a form of Cryopyrin-Associated Periodic Syndromes (CAPS) called Neonatal-Onset Multisystem Inflammatory Disease (NOMID) & 3) Treat people with Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Paras Biopharmaceuticals have worked very extensively on Anakinra and have development, substantial data (unique program) Anakinra is "off patent" For further development and registration / approval, very limited further expenses are to made and hence the partnership. Furthermore, Paras Biopharmaceuticals seems to be the only company other than the innovator on such program. Paras Biopharmaceuticals looks to mature maximum value to the pool / joint sharing for further growth / return / rewards from the program. If you have an interest in the product and would like to know more, we would welcome the opportunity to set up a onsite meeting.

Paras Biopharmaceuticals Finland Oy

  • FI
  • 2018
    On CPHI since
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical

Paras Biopharmaceuticals Finland Oy

  • FI
  • 2018
    On CPHI since
  • 25 - 49
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical

More Products from Paras Biopharmaceuticals Finland Oy (4)

  • RapidEK® (Recombinant Enterokinase)

    Product RapidEK® (Recombinant Enterokinase)

    Paras Biopharma has developed and is offering Recombinant Bioprocess enzymes. This includes Recombinant Enterokinase (RapidEK®). As a type 2 transmembrane serine protease, enterokinase is ideally suited for the biotechnological and biochemical removal of fusion proteins and cleavage of tags after purifica...
  • RapidTEV® Protease (Recombinant TEV Protease)

    Product RapidTEV® Protease (Recombinant TEV Protease)

    Paras Biopharma has developed and is offering Recombinant Bioprocess enzymes including Recombinant Tev Protease (RapidTEV®). RapidTEV® Protease is a site-specific protease that has been engineered for enhanced activity and greater stability. Due to its high specificity it is frequently used for the clea...
  • Rasburicase Biosimilar candidate

    Product Rasburicase Biosimilar candidate

    Paras Biopharmaceuticals has been intensively working on a Romiplostim biosimilar known as Elitek™ / Fasturtec™) and has progressively achieved success. The company plans to mature good value within its Rasburicase asset and would like to highlight the following points / highlights to gauge your level of ...
  • Romiplostim Biosimilar Candidate

    Product Romiplostim Biosimilar Candidate

    Due to the complex nature of the product, Paras Biopharmaceuticals has been intensively working on this complex drug (Nplate™) for over 6 years and has progressively achieved success. The company plans to mature good value within its Romiplostim asset (Biosimilar) and would like to highlight the following...